Lucid Diagnostics Inc. Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Lucid Diagnostics Inc. has an operating margin of -1059.6%, meaning the company retains $-1060 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -1996.8% the prior year.
Lucid Diagnostics Inc.'s revenue surged 79.0% year-over-year to $4.3M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Lucid Diagnostics Inc. has elevated debt relative to equity (D/E of 4.70), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.
Lucid Diagnostics Inc.'s current ratio of 1.07 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 23/100, which could limit financial flexibility.
Lucid Diagnostics Inc. passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Lucid Diagnostics Inc. generates $0.97 in operating cash flow (-$44.1M OCF vs -$45.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Lucid Diagnostics Inc. earns $-1771.2 in operating income for every $1 of interest expense (-$46.1M vs $26K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Lucid Diagnostics Inc. (LUCD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Lucid Diagnostics Inc. generated $4.3M in revenue in fiscal year 2024. This represents an increase of 79.0% from the prior year.
Lucid Diagnostics Inc.'s EBITDA was -$44.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 2.4% from the prior year.
Lucid Diagnostics Inc. reported -$45.5M in net income in fiscal year 2024. This represents an increase of 13.6% from the prior year.
Lucid Diagnostics Inc. earned $-1.05 per diluted share (EPS) in fiscal year 2024. This represents an increase of 16.7% from the prior year.
Lucid Diagnostics Inc. held $22.4M in cash against $0 in long-term debt as of fiscal year 2024.
Lucid Diagnostics Inc. had 67M shares outstanding in fiscal year 2024. This represents an increase of 58.2% from the prior year.
Lucid Diagnostics Inc.'s operating margin was -1059.6% in fiscal year 2024, reflecting core business profitability. This is up 937.2 percentage points from the prior year.
Lucid Diagnostics Inc.'s net profit margin was -1047.6% in fiscal year 2024, showing the share of revenue converted to profit. This is up 1121.5 percentage points from the prior year.
Lucid Diagnostics Inc. invested $6.0M in research and development in fiscal year 2024. This represents a decrease of 17.4% from the prior year.
LUCD Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M+4.1% | $1.2M+40.5% | $828K-30.8% | $1.2M+22.6% | $976K-2.5% | $1.0M-3.8% | $1.0M+32.8% | $783K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $1.3M+1.4% | $1.3M-12.1% | $1.4M-1.7% | $1.5M+5.9% | $1.4M-8.6% | $1.5M-21.7% | $1.9M+18.7% | $1.6M |
| SG&A Expenses | $5.6M-0.2% | $5.6M-8.8% | $6.2M+5.1% | $5.9M+20.5% | $4.9M+19.6% | $4.1M-3.2% | $4.2M-2.7% | $4.3M |
| Operating Income | -$11.8M-3.3% | -$11.4M+8.8% | -$12.5M-0.9% | -$12.4M-10.6% | -$11.2M-3.7% | -$10.8M+5.8% | -$11.5M-2.9% | -$11.1M |
| Interest Expense | $2K-66.7% | $6K-33.3% | $9K+28.6% | $7K+16.7% | $6K-50.0% | $12K+9.1% | $11K-92.6% | $149K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$10.4M-134.2% | -$4.4M+83.5% | -$26.9M-133.2% | -$11.5M-4.9% | -$11.0M-3.7% | -$10.6M+2.0% | -$10.8M+23.8% | -$14.2M |
| EPS (Diluted) | $-0.10-25.0% | $-0.08+84.6% | $-0.52-205.9% | $-0.17+26.1% | $-0.23+42.5% | $-0.40-60.0% | $-0.25+26.5% | $-0.34 |
LUCD Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $53.2M+37.6% | $38.7M+17.9% | $32.8M+6.8% | $30.7M-10.0% | $34.1M+6.4% | $32.0M+17.5% | $27.3M-18.0% | $33.2M |
| Current Assets | $49.8M+47.3% | $33.8M+22.9% | $27.5M+9.5% | $25.1M-10.0% | $27.9M+1.3% | $27.6M+25.0% | $22.1M-19.2% | $27.3M |
| Cash & Equivalents | $47.3M+52.1% | $31.1M+23.3% | $25.2M+12.9% | $22.4M-10.3% | $24.9M+0.6% | $24.8M+31.1% | $18.9M-21.4% | $24.1M |
| Inventory | $486K-3.8% | $505K+4.3% | $484K+41.9% | $341K-50.1% | $683K+66.6% | $410K+47.5% | $278K | N/A |
| Accounts Receivable | $550K+47.5% | $373K+511.5% | $61K+35.6% | $45K-71.9% | $160K+226.5% | $49K+8.9% | $45K+114.3% | $21K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $27.4M-11.2% | $30.8M-19.3% | $38.2M+50.7% | $25.3M+39.6% | $18.1M-10.0% | $20.2M-31.9% | $29.6M-3.6% | $30.7M |
| Current Liabilities | $26.2M-10.9% | $29.4M-19.5% | $36.6M+55.5% | $23.5M+47.2% | $16.0M-20.0% | $20.0M-32.0% | $29.4M-2.8% | $30.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $25.8M+228.6% | $7.9M+246.2% | -$5.4M-199.7% | $5.4M-66.3% | $16.0M+34.3% | $11.9M+614.7% | -$2.3M-190.4% | $2.6M |
| Retained Earnings | -$258.1M-4.2% | -$247.7M-3.3% | -$239.8M-17.7% | -$203.8M-13.3% | -$179.9M-6.5% | -$168.8M-12.0% | -$150.7M-7.7% | -$139.9M |
LUCD Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.9M-3.3% | -$10.5M+15.4% | -$12.5M-26.3% | -$9.9M+14.0% | -$11.5M+9.0% | -$12.6M-26.4% | -$10.0M-13.6% | -$8.8M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$28K-12.0% | -$25K+73.1% | -$93K+64.1% | -$259K | $0+100.0% | -$37K+78.9% | -$175K-1150.0% | -$14K |
| Financing Cash Flow | $27.1M+64.8% | $16.5M+6.6% | $15.4M-14.2% | $18.0M+54.7% | $11.6M-37.2% | $18.5M+270.4% | $5.0M+1718.2% | $275K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
LUCD Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -971.0%+7.8pp | -978.9%+529.2pp | -1508.1%-474.3pp | -1033.8%+113.0pp | -1146.7%-68.6pp | -1078.1%+23.1pp | -1101.3%+320.0pp | -1421.2% |
| Net Margin | -858.5%-476.9pp | -381.7%+2868.1pp | -3249.8%-2285.6pp | -964.2%+163.4pp | -1127.6%-67.4pp | -1060.1%-18.8pp | -1041.4%+773.2pp | -1814.6% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -19.5%-8.1pp | -11.5%+70.6pp | -82.0%-44.5pp | -37.6%-5.3pp | -32.3%+0.9pp | -33.1%+6.6pp | -39.7%+3.0pp | -42.7% |
| Current Ratio | 1.90+0.8 | 1.15+0.4 | 0.75-0.3 | 1.07-0.7 | 1.75+0.4 | 1.38+0.6 | 0.75-0.2 | 0.90 |
| Debt-to-Equity | 1.06-2.9 | 3.92+11.0 | -7.10-11.8 | 4.70+3.6 | 1.13-0.6 | 1.69+14.5 | -12.80-24.8 | 12.01 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Lucid Diagnostics Inc.'s annual revenue?
Lucid Diagnostics Inc. (LUCD) reported $4.3M in total revenue for fiscal year 2024. This represents a 79.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Lucid Diagnostics Inc.'s revenue growing?
Lucid Diagnostics Inc. (LUCD) revenue grew by 79% year-over-year, from $2.4M to $4.3M in fiscal year 2024.
Is Lucid Diagnostics Inc. profitable?
No, Lucid Diagnostics Inc. (LUCD) reported a net income of -$45.5M in fiscal year 2024, with a net profit margin of -1047.6%.
What is Lucid Diagnostics Inc.'s earnings per share (EPS)?
Lucid Diagnostics Inc. (LUCD) reported diluted earnings per share of $-1.05 for fiscal year 2024. This represents a 16.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Lucid Diagnostics Inc.'s EBITDA?
Lucid Diagnostics Inc. (LUCD) had EBITDA of -$44.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Lucid Diagnostics Inc.'s operating margin?
Lucid Diagnostics Inc. (LUCD) had an operating margin of -1059.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Lucid Diagnostics Inc.'s net profit margin?
Lucid Diagnostics Inc. (LUCD) had a net profit margin of -1047.6% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Lucid Diagnostics Inc.'s operating cash flow?
Lucid Diagnostics Inc. (LUCD) generated -$44.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Lucid Diagnostics Inc.'s total assets?
Lucid Diagnostics Inc. (LUCD) had $30.7M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Lucid Diagnostics Inc. spend on research and development?
Lucid Diagnostics Inc. (LUCD) invested $6.0M in research and development during fiscal year 2024.
How many shares does Lucid Diagnostics Inc. have outstanding?
Lucid Diagnostics Inc. (LUCD) had 67M shares outstanding as of fiscal year 2024.
What is Lucid Diagnostics Inc.'s current ratio?
Lucid Diagnostics Inc. (LUCD) had a current ratio of 1.07 as of fiscal year 2024, which is considered adequate.
What is Lucid Diagnostics Inc.'s debt-to-equity ratio?
Lucid Diagnostics Inc. (LUCD) had a debt-to-equity ratio of 4.70 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Lucid Diagnostics Inc.'s return on assets (ROA)?
Lucid Diagnostics Inc. (LUCD) had a return on assets of -148.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Lucid Diagnostics Inc.'s cash runway?
Based on fiscal year 2024 data, Lucid Diagnostics Inc. (LUCD) had $22.4M in cash against an annual operating cash burn of $44.1M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Lucid Diagnostics Inc.'s Piotroski F-Score?
Lucid Diagnostics Inc. (LUCD) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Lucid Diagnostics Inc.'s earnings high quality?
Lucid Diagnostics Inc. (LUCD) has an earnings quality ratio of 0.97x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Lucid Diagnostics Inc. cover its interest payments?
Lucid Diagnostics Inc. (LUCD) has an interest coverage ratio of -1771.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Lucid Diagnostics Inc.?
Lucid Diagnostics Inc. (LUCD) scores 31 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.